Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Leukemia 7Lymphoma, Follicular 6Leukemia, B-Cell 6Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Hairy Cell 4Lymphoma 3Lymphoma, Mantle-Cell 2Bronchiolitis Obliterans Syndrome 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Recurrence 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphatic Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Hereditary Sensory and Autonomic Neuropathies 1Heart Failure 1Disease 1Chromosome 17 deletion 1Anemia 1

Interventions

blinatumomab 4fludarabine 3Rituximab 3Cyclophosphamide 3ponatinib 2ibrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bone Marrow Transplantation 2venetoclax 1tetulomab tetraxetan lu-177 1pomalidomide 1obinutuzumab 1durvalumab 1dacetuzumab 1amonafide 1acalabrutinib 1Tinzaparin 1Lutetium-177 1Lutetium 1Lenalidomide 1Imatinib Mesylate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × obinutuzumab × Other hematologic neoplasm × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡